Stryker Corporation (NYSE:SYK – Get Free Report) VP Robert Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stryker Stock Down 0.6%
Shares of Stryker stock traded down $1.90 on Friday, reaching $305.73. 6,064,642 shares of the company were exchanged, compared to its average volume of 2,296,474. The stock’s 50 day moving average price is $322.61 and its 200-day moving average price is $348.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a market cap of $117.21 billion, a P/E ratio of 35.39, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.
Stryker Dividend Announcement
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the company. Citigroup lowered their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Evercore set a $355.00 price target on Stryker in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price target on Stryker in a research note on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.
Read Our Latest Analysis on Stryker
Institutional Trading of Stryker
Several large investors have recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new position in shares of Stryker during the 2nd quarter worth $205,000. Marshall Wace LLP raised its stake in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC acquired a new position in shares of Stryker during the 2nd quarter worth $219,000. Finally, HUB Investment Partners LLC acquired a new position in shares of Stryker during the 2nd quarter worth $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
About Stryker
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
- Five stocks we like better than Stryker
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
